Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Chordia Therapeutics Inc. ( (JP:190A) ) is now available.
Chordia Therapeutics Inc. announced a change in its major shareholder, as Innovation Kyoto 2016 Investment Limited Liability Partnership reduced its voting rights from 10.14% to 9.99% due to the sale of common stock. This change is not expected to impact the company’s management or business performance.
More about Chordia Therapeutics Inc.
Chordia Therapeutics Inc. is a company operating in the pharmaceutical industry, focusing on the development of innovative therapies. The company is based in Fujisawa City, Kanagawa Prefecture, Japan, and is led by Chief Executive Officer Hiroshi Miyake.
Average Trading Volume: 874,392
Technical Sentiment Signal: Strong Sell
See more insights into 190A stock on TipRanks’ Stock Analysis page.

